Health is our mission

Announcements

 

 

Richter and Mycovia signed a series of agreements for the commercialization and manufacture of a novel oral antifungal to treat RVVC2220<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2019.00000000000<p><strong>​</strong><span lang="EN-US"><strong>Gedeon Richter Plc. (“Richter”) and Mycovia Pharmaceuticals, Inc. (“Mycovia”) today announced that they have entered into an exclusive license and development and technology transfer agreement to commercialize and manufacture VT-1161, currently in Phase III clinical trials for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC). VT-1161 is designed to be highly selective and have improved efficacy, and VT-1161 may avoid side effects that limit the use of current antifungals in the treatment of RVVC. The geographic scope of the license agreement covers Europe, Russia, the other CIS countries, Latin America and Australia.</strong></span></p>2019-10-15T22:00:00Z10/16/2019 5:51:29 AMhttp://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Composition of share capital and voting rights 2205<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2019.000000000002019-09-29T22:00:00Z9/30/2019 3:11:25 PM43http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Richter announces approval in Japan of its licensed-out biosimilar teriparatide 2189<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2019.00000000000<p>​</p><p style="text-align&#58;justify;">Gedeon Richter Plc. (&quot;Richter&quot;) today announced that its license partner Mochida Pharmaceutical Co., Ltd. (&quot;Mochida&quot;) received marketing authorization from the Japanese Ministry of Health, Labour and Welfare (MHLW) for biosimilar teriparatide developed by Richter-Helm BioTec GmbH &amp; Co. KG.</p><p style="text-align&#58;justify;">&#160;</p>2019-09-19T22:00:00Z9/20/2019 7:49:11 AM181http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Change in the Board of Directors of Gedeon Richter Plc.2180<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2019.000000000002019-09-01T22:00:00Z9/2/2019 4:58:26 PM231http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Composition of share capital and voting rights2177<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2019.000000000002019-08-29T22:00:00Z8/30/2019 1:13:08 PM90http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Extraordinary Announcement2174<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2019.000000000002019-08-20T22:00:00Z8/21/2019 11:50:51 AM1514http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Richter launched Terrosa®, its biosimilar teriparatide across Europe2173<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2019.00000000000<p>​Gedeon Richter Plc. (&quot;Richter&quot;) today announced that it has launched its biosimilar teriparatide, Terrosa<strong><sup>®</sup></strong> in Europe. The product is approved in adults for the same indications as Eli Lilly's Forsteo<strong><sup>®</sup></strong>, i.e. used for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture and treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.</p>2019-08-19T22:00:00Z8/20/2019 6:00:42 AM540http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Mitsubishi received regulatory approval for Cariprazine in part of ASEAN (Singapore and Thailand)2170<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2019.00000000000​<span lang="EN-US">Gedeon Richter Plc (“Richter”) today announced that Mitsubishi Tanabe Pharma Corporation’s (“MTPC”) subsidiaries in ASEAN obtained the regulatory approval of cariprazine for the treatment of schizophrenia. Current approvals have been granted in Singapore and in Thailand.</span><br><br>2019-08-07T22:00:00Z8/21/2019 11:45:35 AM256http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Composition of share capital and voting rights 2165<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2019.000000000002019-07-30T22:00:00Z7/31/2019 11:15:53 AM147http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Richter and Hikma signed a license and supply agreement for the commercialisation of cariprazine in the MENA region2121<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2019.00000000000<p>​Gedeon Richter Plc (&quot;Richter&quot;) and Hikma Pharmaceuticals Plc (&quot;Hikma&quot;) today announced the signing of an exclusive license agreement to commercialize cariprazine, a novel antipsychotic in certain Middle East and North African (MENA) markets.</p>2019-07-24T22:00:00Z7/25/2019 6:39:35 AM381http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx